[1] Driscoll DO,Darragh H,Ciaran J,et al.18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer. Abdom imaging,2015,40(1):127-133. [2] Ilknur A,Hasan O,Olga Meltem A,et al.Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT. Ann Hematol,2015,94(9):1567-1575. [3] 刘国兵,李艳丽,胡鹏程,等. 肝功能指标及慢性肝炎病毒感染状态对肝脏摄取18F-FDG的影响.中华核医学与分子影像杂志,2015,35(4):254-257. [4] 刘国兵,李艳丽,呼岩,等.血液本底对肝脏18F-FDG SUV 的影响及校正方法探讨. 中华核医学与分子影像杂志,2016,36(2):166-170. [5] Zeynep GO,Serkan K,Ayse Kubat U,et al.Comparison of ga-68-dotatate PET/CT,F-18-FDG PET-CT and Tc-99m-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun,2015,36(3):242-250. [6] Rajeev K,Gaurav M,Anurag L,et al.Comparison of I-131-MIBG,Ga-68-DOTANOC PET/CT and F-18-FDG PET/CT scans in a patient with extra adrenal paraganglioma associated with SDH-B gene mutation. Clin Nucl Med,2015,40(5):439-441. [7] Hiroshi H,Terushige M,Yuka Y,et al.Prognostic value comparison between F-18-FLT PET/CT and F-18-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer. Clin Nucl Med,2015,40(6):464-468. [8] Konstantinos ZG,Felipe B,Martin H,et al.Clinical evaluation of PET image quality as a function of acquisition time in a new TOF-PET/MRI compared to TOF-PET/CT-Initial results. Mol Imaging Biol,2015,17(5):735-744. [9] Mohsen B,Thomas K,Silke H,et al.Bay 1075553 PET-CT for staging and restaging prostate cancer patients:xomparison with [F-18] fluorocholine PET-CT(phase 1 study). Mol Imaging Biol,2015,17(3):424-433. [10] Miltenyi Z,Barna S,Garai I,et al.Prognostic value of interim and restaging PET/CT in Hodgkin lymphoma:Results of the CHEAP(Chemotherapy Effectiveness Assessment by PET/CT) study-long term observation. J Exp Clin Oncol,2015,62(4):627-634. [11] Kubota K,Watanabe H,Murata Y,et al.Effects of blood glucose level on FDG uptake by liver:a FDG-PET/CT study. Nucl Med Biol,2011,38(3):347-351. [12] Kamimura K,Nagamachi S,Wakamatsu H,et al.Associations between liver 18F fluoro-2-deoxy-D-glucose accumulation and various clinical parameters in a Japanese population:influence of the metabolic syndrome. Ann Nucl Med,2010,24(3):157-161. [13] 刘东锋,张峰,潘贤成,等. 18F-FDG PET/CT双时相显像在肝癌诊断中的应用价值探讨.实用肝脏病杂志,2016,19(4):463-466. [14] Batalles SM,Villavicencio RL,Quaranta A,et al.Variations of the hepatic SUV in RELATION to the body mass index in whole body PET-CT studies. Rev Esp Med Nucl Imagen Mol,2013,32(1):26-32. [15] Zhang HJ,Xing W,Kang QQ,et al.Diagnostic value of [F-18] FDG-PET and PET/CT in urinary bladder cancer:a Meta-analysis. J Int Soc Oncodevel Biol Med,2015,36(5):3209-3214. [16] Alessio I,Julien G,Bachellier P,et al.Simultaneous F-18-FD-OPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis further step toward a theranostic approach. Clin Nucl Med,2015,40(6):E334-E335. [17] Braeuning U,Pfannenberg C,Gallwitz B,et al.C-11-methionine PET/CT after inconclusive Tc-99m-MIBI-SPECT/CT for localisa-tion of parathyroid adenomas in primary hyperparathyroidism. Nucl Med,2015,54(1):26-30. [18] Adams Hugo JA,Kwee Thomas C,Fijnheer R,et al.Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma:does bone marrow FDG-PET/CT live up to its promise Acta Radiologica,2015,56(10):1230-1235. [19] De Giorgi U,Caroli P,Scarpi E,et al.F-18-fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging,2015,42(8):1276-1283. [20] 柯比努尔·吐尔逊,韩丹,张跃新,等. 肝硬化患者血清促甲状腺激素和甲状腺素水平变化及其临床意义.实用肝脏病杂志,2017,20(6):764-766. |